Adoptive cell transfer (ACT) of purified naive, stem cell memory, and central memory T cell subsets results in superior persistence and antitumor immunity compared with ACT of populations containing more-differentiated effector memory and effector T cells. Despite a clear advantage of the less-differentiated populations, the majority of ACT trials utilize unfractionated T cell subsets. Here, we have challenged the notion that the mere presence of less-differentiated T cells in starting populations used to generate therapeutic T cells is sufficient to convey their desirable attributes. Using both mouse and human cells, we identified a T cell–T cell interaction whereby antigen-experienced subsets directly promote the phenotypic, functional, and metabolic differentiation of naive T cells. This process led to the loss of less-differentiated T cell subsets and resulted in impaired cellular persistence and tumor regression in mouse models following ACT. The T memory–induced conversion of naive T cells was mediated by a nonapoptotic Fas signal, resulting in Akt-driven cellular differentiation. Thus, induction of Fas signaling enhanced T cell differentiation and impaired antitumor immunity, while Fas signaling blockade preserved the antitumor efficacy of naive cells within mixed populations. These findings reveal that T cell subsets can synchronize their differentiation state in a process similar to quorum sensing in unicellular organisms and suggest that disruption of this quorum-like behavior among T cells has potential to enhance T cell–based immunotherapies.
Christopher A. Klebanoff, Christopher D. Scott, Anthony J. Leonardi, Tori N. Yamamoto, Anthony C. Cruz, Claudia Ouyang, Madhu Ramaswamy, Rahul Roychoudhuri, Yun Ji, Robert L. Eil, Madhusudhanan Sukumar, Joseph G. Crompton, Douglas C. Palmer, Zachary A. Borman, David Clever, Stacy K. Thomas, Shashankkumar Patel, Zhiya Yu, Pawel Muranski, Hui Liu, Ena Wang, Francesco M. Marincola, Alena Gros, Luca Gattinoni, Steven A. Rosenberg, Richard M. Siegel, Nicholas P. Restifo
Title and authors | Publication | Year |
---|---|---|
T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy
Tori N. Yamamoto, Ping-Hsien Lee, Suman Kumar Vodnala, Devikala Gurusamy, Rigel Kishton, Zhiya Yu, Arash Eidizadeh, Robert Eil, Jessica Fioravanti, Luca Gattinoni, James N. Kochenderfer, Terry J Fry, Bulent Arman Aksoy, Jeffrey Hammerbacher, Anthony C Cruz, Richard Siegel, Nicholas P. Restifo, Christopher A. Klebanoff |
Journal of Clinical Investigation | 2019 |
Rethinking Communication in the Immune System: The Quorum Sensing Concept
L Antonioli, C Blandizzi, P Pacher, M Guilliams, G Haskó |
Trends in Immunology | 2019 |
Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines
CJ Dwyer, HM Knochelmann, AS Smith, MM Wyatt, GO Rivera, DC Arhontoulis, E Bartee, Z Li, MP Rubinstein, CM Paulos |
Frontiers in immunology | 2019 |
Generation and Immune Regulation of CD4+CD25−Foxp3+ T Cells in Chronic Obstructive Pulmonary Disease
JH Wu, M Zhou, Y Jin, ZJ Meng, XZ Xiong, SW Sun, SY Miao, HL Han, XN Tao |
Frontiers in immunology | 2019 |
Emerging Cellular Therapies for Cancer
S Guedan, M Ruella, CH June |
Annual Review of Immunology | 2019 |
TRAIL and FasL Functions in Cancer and Autoimmune Diseases: Towards an Increasing Complexity
Rossin, Miloro, Hueber |
Cancers | 2019 |
HOXC10 promotes migration and invasion via the WNT-EMT signaling pathway in oral squamous cell carcinoma
BW Dai, ZM Yang, P Deng, YR Chen, ZJ He, , S Zhang, HJ Wu, ZH Ren |
Journal of Cancer | 2019 |
T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance
SS Chandran, CA Klebanoff |
Immunological Reviews | 2019 |
Aging boosts antiviral CD8+T cell memory through improved engagement of diversified recall response determinants
B Davenport, J Eberlein, TT Nguyen, F Victorino, K Jhun, H Abuirqeba, V van der Heide, P Heeger, D Homann, GF Rall |
PLoS pathogens | 2019 |
Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy
S Stock, M Schmitt, L Sellner |
International journal of molecular sciences | 2019 |
Comparison of IL-2 vs IL-7/IL-15 for the generation of NY-ESO-1-specific T cells
W Gong, JM Hoffmann, S Stock, L Wang, Y Liu, ML Schubert, B Neuber, A Hückelhoven-Krauss, U Gern, A Schmitt, C Müller-Tidow, H Shiku, M Schmitt, L Sellner |
Cancer Immunology, Immunotherapy | 2019 |
Developing neoantigen-targeted T cell–based treatments for solid tumors
TN Yamamoto, RJ Kishton, NP Restifo |
Nature Medicine | 2019 |
Cell-Based IL-15:IL-15Rα Secreting Vaccine as an Effective Therapy for CT26 Colon Cancer in Mice
Van Anh Do Thi, Hyung Min Jeon, Sang Min Park, Hayyoung Lee, Young Sang Kim |
Molecules and Cells | 2019 |